Conditions: Advanced Solid Tumors
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 54
Healthy volunteers: no

Brief summary:
The purpose of this study is to find a safe and tolerable dose of Lipotecan® when administered to patients with advanced solid tumors.

Detailed description:
Lipotecan® is a drug product of TLC388 HCl, which is a potent camptothecin analog with cytotoxic activities against a variety of human tumor cell lines in vitro and anti-tumor activities in several xenograft models with human tumor cell lines. Structurally, TLC388 HCl is related to other camptothecins, but it has been chemically modified to improve stability and potency, and to minimize toxicities.

Arms:
arm 1: Intravenous Lipotecan (TLC388 HCl for Injection)

Interventions: intervention 1: Lipotecan
Intervention descriptions: intervention 1: Lipotecan IV day 1, 8, 15

Protocol document: